TABLE 1.
Detailed demographics of enrolled participants
| Characteristics | Normal control (n = 30) | Breast cancer (n = 20) |
|---|---|---|
| Age‐years | ||
| Median (range) | 51 (42–67) | 52 (47–65) |
| HER2 status‐no. (%) | ||
| IHC(3+) | 14 | |
| IHC(2+) and FISH(+) | 6 | |
| Estrogen receptor status (%) | ||
| Positive | 8 | |
| Negative | 12 | |
| No. of metastatic sites | ||
| 1 | 12 | |
| 2 | 4 | |
| 3 | 1 | |
| ≥4 | 0 | |
| Clinical stage | ||
| I | 1 | |
| II | 9 | |
| III | 10 | |
| Site of metastasis (%) | ||
| Lymph node | 20 | |
| Lung | 3 | |
| Pleura | 1 | |
| Bone | 2 | |
| Liver | 0 | |
| Brain | 0 | |
| Others | 0 | |
| Treatment regimens | ||
| Paclitaxel + trastuzumab | 9 | |
| Docetaxel + trastuzumab | 11 | |
| Trastuzumab resistant | 8 | |
| Trastuzumab responsive | 12 | |